# EDGAR Filing Document

**Accession Number:** 0000001800
**File Stem:** 0001104659-25-114995
**Filing Date:** 2025-11
**Character Count:** 9262
**Document Hash:** e26a5747737190c1ebf5401fe2af6352
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-114995.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001104659-25-114995

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251118

**ITEM INFORMATION**: Temporary Suspension of Trading Under Registrant's Employee Benefit Plans

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251121

**DATE AS OF CHANGE**: 20251121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-02189
- **FILM NUMBER:** 251507949

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

?xml version='1.0' encoding='ASCII'?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**November 18, 2025**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Illinois** | **1-2189** | **36-0698440** |
| (State or other Jurisdiction | (Commission File Number) | (IRS Employer |
| of Incorporation) |  | Identification No.) |

---

**100 Abbott Park Road**

**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading <br> Symbol(s)** | **Name of Each Exchange <br> on Which Registered** |
| Common Shares, Without Par Value | ABT | New York Stock Exchange<br> NYSE Texas |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.04** | **Temporary Suspension of Trading Under Registrant's Employee Benefit Plans** |

---

On November 18, 2025, Abbott Laboratories ("Abbott") received a notice from the plan administrator of the Abbott Laboratories Stock Retirement Plan ("U.S. Plan") and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) ("P.R. Plan"; collectively, the "Plans") pursuant to Section 101(i)(2)(E) of the Employee Retirement Income Security Act of 1974 regarding a blackout period (the "Blackout Period") under the Plans. The Blackout Period is required because the Plans are making certain administrative changes, including changing the recordkeeper, changing the trustee for certain funds of the U.S. Plan, and changing the custodian of certain funds of the P.R. Plan.

During the Blackout Period, Plan participants will be unable to engage in transactions involving the assets held in their Plan accounts, including changing contribution rates, directing or diversifying investments (including investments in Abbott common shares), or obtaining a Plan loan, withdrawal, or distribution.

As described more fully in the Notice (as defined below), the Blackout Period is expected to begin on December 24, 2025 at 12 p.m. CST and expected to end during the week of January 11, 2026. During the Blackout Period and for two years after the ending date of the Blackout Period, a security holder or other interested person may obtain, without charge, information regarding the Blackout Period, including the actual beginning and ending dates of the Blackout Period, by submitting a request to Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, Attn: Divisional Vice President, Compensation and Benefits; (224) 667-6100.

On November 21, 2025, Abbott sent a notice to its directors and executive officers (the "Notice") informing them of the Blackout Period and the restrictions on trading in Abbott common shares that apply to them during the Blackout Period, pursuant to Section 306 of the Sarbanes-Oxley Act of 2002 and Rule 104 of Regulation BTR. A copy of the Notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

<u>Exhibit No.</u> <u>Exhibit</u>

[99.1](tm2531676d1_ex99-1.htm) [Notice provided to directors and executive officers of Abbott Laboratories on November 21, 2025.](tm2531676d1_ex99-1.htm)

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ABBOTT LABORATORIES** | **ABBOTT LABORATORIES** |
| Date: November 21, 2025 | By: | /s/ Philip P. Boudreau |
|  |  | Philip P. Boudreau |
|  |  | Executive Vice President, Finance and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Notice of Blackout Period to**

**Directors and Executive Officers of Abbott Laboratories**

This notice explains certain restrictions on your investments in securities of Abbott Laboratories ("Abbott") during an upcoming retirement plan blackout period. As a director or executive officer of Abbott, you are subject to restrictions under Section 306(a) of the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley") and Rule 104 of Regulation BTR under the Securities Exchange Act of 1934 ("Regulation BTR").

*Reason for Blackout Period*: In January 2026, the Abbott Laboratories Stock Retirement Plan ("U.S. Plan") and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) ("P.R. Plan"; collectively, the "Plans") will be changing recordkeepers, the U.S. Plan will be changing trustees for certain of its investment funds, and the P.R. Plan will be changing custodians for certain of its investment funds. During this transition period, which is called a "Blackout Period," Plan participants will be unable to engage in transactions involving the assets held in their Plan accounts, including changing contribution rates, directing investment of future contributions or diversifying investments (including investments in Abbott common shares), making rollover contributions to the Plans, obtaining a plan loan, requesting a withdrawal or distribution from the Plans, or viewing their Plan accounts.

*Length of Blackout Period*: The Blackout Period is expected to begin on December 24, 2025 at 12 p.m. CST and is expected to end during the week of January 11, 2026. You can determine whether the Blackout Period has begun or ended by calling Sean Treacy, Divisional Vice President, Compensation and Benefits, at (224) 667-6100.

*Trading Restrictions*: As you know, you are already precluded during this Blackout Period from trading in Abbott securities under Abbott's general insider trading policy, which disallows trades during specific periods (in this case, from December 15, 2025, until after the fourth quarter earnings release).

Nevertheless, we are required by Sarbanes-Oxley and Regulation BTR to inform you that, during the Blackout Period, you are generally prohibited from directly or indirectly purchasing, selling, or otherwise transferring any equity security of Abbott. These restrictions apply regardless of whether you participate in either of the Plans. The Blackout Period will apply even if Abbott's general insider trading policy prohibition on trading is lifted.

If you have any questions concerning the Blackout Period, please contact Mr. Treacy by phone at (224) 667-6100, or you may write to Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, Attn: Divisional Vice President, Compensation and Benefits.